History

Our company´s development over time

2011 – Launch of P.L.E.A.S.E.®  Professional

  • A compact and portable bench top system incorporating breakthrough, powerful diode-pumped Er:YAG fractional ablative laser technology.
  • Applications in conventional and aesthetic dermatology as well as general medicine.
  • Active epidermal immunisation achieved with recombinant allergy in animal proof of concept study.

2010 – Clinical proof of concept for infertility protein

  • Therapeutic blood levels achieved with FSH (protein 32 KDa, for egg cell 
maturisation).
  • CE-Mark received for P.L.E.A.S.E.® Professional.
  • Large financing round completed.

2009 – Clinical proof of concept for infertility peptide

  • Successful clinical proof of concept with triptorelin (peptide hormone for 
downregulation in infertility treatment). P.L.E.A.S.E.® works with peptides 
and proteins.
  • Very promising clinical data with FSH (protein 32 KDa, for egg cell maturisation).
  • Animal study in collaboration with recombinant allergen company underway to test active epidermal immunisation principle with P.L.E.A.S.E.® avoiding
 multiple injections.

2008 – P.L.E.A.S.E.® device CE marked

  • First hand-held lasers produced receive the CE-mark.
  • ISO 13485 certification achieved, device production facilities established.
  • Virtual pharma firm established with a preclinical centre in Geneva, patch and clinical 
development in Germany and API suppliers in Europe. Pantec BS is GDP
 (Good Distribution Practises) certified.
  • Collaboration agreement with Pharma company in place.

2007 – P.L.E.A.S.E.® platform developed

  • Most efficient 3 micron laser system of its size developed by the PBS team.
  • Six drugs tested in vitro. They all permeate in clinically relevant concentrations.
  • 2006 Human clinical cutaneous tolerability study concluded positively.  
  • The study conducted with 12 volunteers resulted in discrete pores with little or no 
discomfort for the patients and no thermal damages of the pore adjacent skin layers.
  • The way for human IVF hormone bioavailability studies is now open.

2006 – The founding of Pantec Biosolutions AG

Pantec Biosolutions AG is founded with the mission of developing and commercialising 
an intraepidermal solution, which consists of a device for the pre-treatment of human 
skin and novel drug patches for application after pre-treatment. The goal is to 
deliver IVF hormones and other large molecules intraepidermally.